2023
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriodCovid-19 vaccine acceptance among individuals incarcerated in Connecticut state jails
Lind M, Kennedy B, Nieto M, Houde A, Sosensky P, Borg R, Cummings D, Ko A, Richeson R. Covid-19 vaccine acceptance among individuals incarcerated in Connecticut state jails. Health & Justice 2023, 11: 16. PMID: 36913159, PMCID: PMC10009345, DOI: 10.1186/s40352-023-00216-x.Peer-Reviewed Original ResearchCOVID-19 vaccine programVaccine acceptanceVaccination programCOVID-19 vaccine acceptanceAge-adjusted hazardRetrospective cohort analysisOutcome of vaccinationTime-varying exposureTime of incarcerationVaccination ratesVaccine programVaccine offerCohort analysisVaccinationSurvival analysisStudy periodIncarcerated populationsLow levelsIncarcerationResidentsJailPopulationIntake
2022
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABooster
2021
Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements
Ticona J, Nery N, Victoriano R, Fofana MO, Ribeiro GS, Giorgi E, Reis MG, Ko AI, Costa F. Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements. Vaccines 2021, 9: 951. PMID: 34579188, PMCID: PMC8472908, DOI: 10.3390/vaccines9090951.Peer-Reviewed Original ResearchVaccine hesitancyCOVID-19 vaccine acceptanceCOVID-19 vaccine hesitancyImportance of vaccinationCOVID-19 infectionCOVID-19 vaccinePotential side effectsCOVID-19Vaccine efficacyCOVID-19 casesVaccine acceptanceVaccine intentionsGeneral populationHigh incidenceSpecific treatmentSide effectsHealth historySalvador-BrazilMultivariate analysisYounger ageVaccineSlum residentsSlum settingsVaccinationSlum communities